论文部分内容阅读
目的:探讨血浆脑钠肽(BNP)水平在心力衰竭(CHF)T和呼吸困难诊断中的应用。方法:采用免疫荧光快速测试法测定56例已确诊心衰患者、40例心源性呼吸困难患者、29例肺源性呼吸困难患者和30例健康人血浆BNP的含量。结果:心衰组患者血浆BNP水平明显高于对照组,差异显著(P<0.01);心源性呼吸困难组患者的BNP值水平(1032.2±879.8 pg/ml)与肺源性呼吸困难组患者的BNP值水平(67.1±43.6 pg/ml)比较有显著性差异(P<0.01)。结论:检测BNP水平可为临床诊断CHF及心源性与肺源性呼吸困难的鉴别诊断提供重要依据。
Objective: To investigate the application of plasma brain natriuretic peptide (BNP) in the diagnosis of heart failure (CHF) T and dyspnea. Methods: The plasma BNP levels in 56 patients with confirmed heart failure, 40 patients with cardiogenic dyspnea, 29 patients with pulmonary-derived dyspnea and 30 healthy individuals were determined by immunofluorescence rapid test. Results: Plasma BNP levels in patients with heart failure were significantly higher than those in the control group (P <0.01). BNP levels (1032.2 ± 879.8 pg / ml) in patients with cardiorespiratory dysfunction were significantly higher than those in patients with pulmonary dyspnea BNP levels (67.1 ± 43.6 pg / ml) were significantly different (P <0.01). Conclusion: The detection of BNP levels may provide an important basis for the differential diagnosis of CHF and cardiogenic pulmonary dyspnea.